User login
Key clinical point: Compared with the usual emollient and cleanser skincare routine, an emollient plus balm combination significantly improved pruritus in patients with moderate-to-severe atopic dermatitis (AD) receiving systemic treatment.
Major finding: Patients treated with an emollient plus balm combination after pre-cleaning with a syndet (emollient “plus” group) vs the usual emollient and cleanser skincare routine (control group) had a significantly greater mean decrease in current pruritus after 70 days (P = .0277) and worse pruritus over the last 24 hours after 42 days (P = .025) of treatment.
Study details: This randomized controlled multicenter study included 57 adult patients with moderate-to-severe AD using systemic treatment who were randomly assigned 1:1 to the emollient “plus” group or the control group.
Disclosures: This study was funded by La Roche-Posay (LRP). Two authors declared being employees of LRP, and some authors declared serving on advisory boards or as speakers, consultants, or investigators in the presented trial or other clinical trials sponsored by various sources, including LRP.
Source: Magnolo N et al. Comparison of different skin care regimens in patients with moderate to severe atopic dermatitis receiving systemic treatment: A randomized controlled trial. J Eur Acad Dermatol Venereol. 2023 (Apr 24). Doi: 10.1111/jdv.18949
Key clinical point: Compared with the usual emollient and cleanser skincare routine, an emollient plus balm combination significantly improved pruritus in patients with moderate-to-severe atopic dermatitis (AD) receiving systemic treatment.
Major finding: Patients treated with an emollient plus balm combination after pre-cleaning with a syndet (emollient “plus” group) vs the usual emollient and cleanser skincare routine (control group) had a significantly greater mean decrease in current pruritus after 70 days (P = .0277) and worse pruritus over the last 24 hours after 42 days (P = .025) of treatment.
Study details: This randomized controlled multicenter study included 57 adult patients with moderate-to-severe AD using systemic treatment who were randomly assigned 1:1 to the emollient “plus” group or the control group.
Disclosures: This study was funded by La Roche-Posay (LRP). Two authors declared being employees of LRP, and some authors declared serving on advisory boards or as speakers, consultants, or investigators in the presented trial or other clinical trials sponsored by various sources, including LRP.
Source: Magnolo N et al. Comparison of different skin care regimens in patients with moderate to severe atopic dermatitis receiving systemic treatment: A randomized controlled trial. J Eur Acad Dermatol Venereol. 2023 (Apr 24). Doi: 10.1111/jdv.18949
Key clinical point: Compared with the usual emollient and cleanser skincare routine, an emollient plus balm combination significantly improved pruritus in patients with moderate-to-severe atopic dermatitis (AD) receiving systemic treatment.
Major finding: Patients treated with an emollient plus balm combination after pre-cleaning with a syndet (emollient “plus” group) vs the usual emollient and cleanser skincare routine (control group) had a significantly greater mean decrease in current pruritus after 70 days (P = .0277) and worse pruritus over the last 24 hours after 42 days (P = .025) of treatment.
Study details: This randomized controlled multicenter study included 57 adult patients with moderate-to-severe AD using systemic treatment who were randomly assigned 1:1 to the emollient “plus” group or the control group.
Disclosures: This study was funded by La Roche-Posay (LRP). Two authors declared being employees of LRP, and some authors declared serving on advisory boards or as speakers, consultants, or investigators in the presented trial or other clinical trials sponsored by various sources, including LRP.
Source: Magnolo N et al. Comparison of different skin care regimens in patients with moderate to severe atopic dermatitis receiving systemic treatment: A randomized controlled trial. J Eur Acad Dermatol Venereol. 2023 (Apr 24). Doi: 10.1111/jdv.18949